Huadong Medicine has obtained approvals for three new products at the start of the year, which is nearly half of last year's total.|Quick read announcement.

1. Huadong Medicine announced today that three products have received approval for market entry, while a total of seven products were approved last year; 2. Among them, a hyaluronic acid product for medical aesthetics and a chemical drug for the treatment of ovarian cancer received domestic approval, while a medical instrument for assessing kidney function received approval in the USA; 3. Huadong Medicine believes that the approvals will not have a significant impact on the company's current financial situation and operational results.

cls.cnJan 20 10:31 ET

The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 08:42 ET

Third quarter dividends change to pre-spring festival dividends? Fulejia and others rely on "spring festival red envelopes" to attract attention | Quick reading of announcements.

① Following three squirrels inc., Fu Er Jia announced a dividend plan before the Spring Festival; ② The so-called dividends before the Spring Festival from the two companies are essentially third quarter dividends; ③ Both companies operate within the consumer sector and are facing certain pressures; ④ This operation may be a response to the policy call for "dividends before the Spring Festival."

cls.cnDec 3, 2024 09:05 ET

Major asset restructuring changes, jinfa labi intends to reduce the acquisition of the target equity to 51% | Speed ​​reading announcement

① Jinfa Labi has terminated the major asset restructuring, changing to the acquisition of 51% equity in Zhuhai Hanfei and Zhongshan Hanfei, which does not constitute a major asset restructuring. ② Jinfa Labi has incurred net income losses for two consecutive years, with revenue of 0.139 billion yuan in the first three quarters, down 7.63% year-on-year, and a net income attributable to shareholders of -9.9525 million yuan.

cls.cnNov 17, 2024 08:46 ET

Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.

①At the earnings conference, fosun pharma indicated that due to the continued expansion of innovative drugs and other factors, the company's performance in Q3 improved year-on-year. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the prompt market entry of injectable type A botulinum toxin in china. ③ The privatization process of henlius and the accessibility of CAR-T products have also attracted significant attention.

cls.cnNov 13, 2024 08:52 ET

The hottest summer Artemisia annua is not selling well chongqing taiji industry Q3 performance decreased by 70% | interpretations

In 2024, the national average temperature is the highest for the same period in history since 1961, but the sales volume of Chongqing Taiji Industry Huoxiang Zhengqi Oral Liquid decreased significantly in the third quarter, with a sharp drop in sales of the main product, leading to a year-on-year decline of over 70% in Chongqing Taiji Industry's profit in the third quarter.

cls.cnOct 24, 2024 09:59 ET